Hamed Alavi - Jan 18, 2023 Form 3 Insider Report for enVVeno Medical Corp (NVNO)

Role
Chief Technology Officer
Signature
/s/ Hamed Alavi
Stock symbol
NVNO
Transactions as of
Jan 18, 2023
Transactions value $
$0
Form type
3
Date filed
1/31/2023, 08:56 PM
Next filing
Dec 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NVNO Stock Options Jan 18, 2023 Common Stock 100K $6.70 Direct F1
holding NVNO Stock Options Jan 18, 2023 Common Stock 126K $6.70 Direct F2
holding NVNO Stock Options Jan 18, 2023 Common Stock 320K $8.20 Direct F3
holding NVNO Stock Options Jan 18, 2023 Common Stock 8K $10.00 Direct F4
holding NVNO Restricted Stock Unit Jan 18, 2023 Common Stock 50K Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock options were issued to the Reporting Person on November 30, 2022 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2025.
F2 The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2024.
F3 The common stock options were issued to the Reporting Person on February 18, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through March 2024.
F4 The common stock options were issued to the Reporting Person on July 18, 2020 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through September 2023.
F5 The Reporting Person was granted 50,000 restricted stock units on November 30, 2021 pursuant to the Plan. The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve.